A new paradigm of quality of care in rheumatoid arthritis: how our new therapeutics have changed the game

Demonstrating the effectiveness of expensive new rheumatoid arthritis (RA) therapeutics is imperative to determine whether the quality of care has improved with the introduction of these agents. Our current RA quality measures are primarily process based, but they must become outcomes based to bette...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 15; no. 5; p. 121
Main Authors Desai, Sonali P, Solomon, Daniel H
Format Journal Article
LanguageEnglish
Published England BioMed Central 01.01.2013
Subjects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Humans
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - standards
Quality Assurance, Health Care - standards
Quality Indicators, Health Care - standards
Quality of Life
Online AccessGet full text

Cover

More Information
Summary:Demonstrating the effectiveness of expensive new rheumatoid arthritis (RA) therapeutics is imperative to determine whether the quality of care has improved with the introduction of these agents. Our current RA quality measures are primarily process based, but they must become outcomes based to better demonstrate quality. New RA quality measures must be multidimensional, accounting for all of the important outcomes in RA: radiographic, functional status, and disease activity. To fully understand the potential benefits of new therapeutics in RA, outcome measures must be integrated with routine practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1478-6354
1478-6362
DOI:10.1186/ar4356